Helius Medical Technologies Announces DMEPOS Accreditation for PoNS
Critical initial step toward US reimbursement
NEWTOWN, Pa., June 20, 2023 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that its Portable Neuromodulation Stimulator (PoNS®) device has been awarded Durable Medical Equipment…
Helius Medical Technologies has recently achieved a significant milestone in its journey towards providing innovative solutions for patients with balance and gait deficits. The Company’s Portable Neuromodulation Stimulator (PoNS®) device has been granted DMEPOS accreditation, marking a critical initial step towards obtaining reimbursement in the United States.
The PoNS® device is a cutting-edge technology that offers a novel therapeutic approach to neuromodulation, specifically designed to address balance and gait issues. By receiving DMEPOS accreditation, Helius Medical Technologies has taken a significant stride towards making this groundbreaking device more accessible to patients in need.
This accreditation not only validates the quality and effectiveness of the PoNS® device but also opens up new possibilities for individuals seeking alternative treatment options for their neurological conditions. By securing reimbursement eligibility, Helius Medical Technologies can potentially reach a broader patient population and make a meaningful impact on the lives of those struggling with balance and gait impairments.
With this recent development, the Company is paving the way for greater adoption and utilization of its innovative neurotechnology, ultimately aiming to improve patient outcomes and enhance overall quality of life. The PoNS® device represents a promising advancement in the field of neuromodulation, offering hope for individuals facing mobility challenges.
As Helius Medical Technologies continues to advance its mission of delivering revolutionary solutions for neurological disorders, the DMEPOS accreditation for the PoNS® device marks a significant milestone in the Company’s pursuit of transforming healthcare through innovative technologies.
How this will affect me:
As a potential patient with balance or gait deficits, the DMEPOS accreditation for the PoNS® device means that you may soon have access to a cutting-edge treatment option that could significantly improve your quality of life. With reimbursement eligibility, the cost barrier for utilizing this innovative neurotechnology may be reduced, making it more accessible to individuals seeking effective solutions for their neurological conditions.
How this will affect the world:
The DMEPOS accreditation for the PoNS® device represents a significant advancement in the field of neurotechnology, paving the way for enhanced treatment options for patients worldwide. By expanding access to innovative neuromodulation technologies like the PoNS®, Helius Medical Technologies is not only transforming healthcare on an individual level but also contributing to broader advancements in neurological care globally.
Conclusion:
The DMEPOS accreditation for the PoNS® device by Helius Medical Technologies is a critical step towards improving patient access to innovative neuromodulation solutions for balance and gait deficits. This milestone not only benefits individuals seeking alternative treatment options but also signifies a positive shift towards advancing neurological care on a global scale. As the Company continues to make strides in the field of neurotechnology, the future holds promising possibilities for patients in need of transformative healthcare solutions.
